bosimidan

Bosimendidan is a vaccine that is primarily used to prevent Japanese encephalitis, a mosquito-borne disease that affects several parts of Asia. The vaccine is a live, attenuated vaccine that was first introduced in the 1970s. It contains a weakened form of the Japanese encephalitis virus, which is incapable of causing severe disease in the recipient.

The vaccine is typically administered in an inactivated form to people who are at high risk of contracting the disease. This includes individuals who live or work in areas where the virus is prevalent, such as rural farmers or construction workers. The vaccine is usually given in a series of two doses, with the first dose followed by a booster dose.

Bosimendidan has been widely used in several Asian countries, including China, India, and Bangladesh. Its use has been supported by the World Health Organization (WHO), which has included the vaccine in its list of WHO-prequalified vaccines. The vaccine has been shown to be safe and effective in preventing Japanese encephalitis, with efficacy rates ranging from 50 to 90 per cent. Side effects of the vaccine are generally mild and may include pain at the injection site, fever, and headache.

More recently, the development of a chimeric subunit vaccine has been reported, which looks promising in providing longer lasting protection against Japanese encephalitis. However, more research is required to further explore its effectiveness, safety and applicability.